GNLX Genelux Corp.: רווח למניה אחת ב-12 החודשים האחרונים

Genelux Corporation brings together leading virologists developing breakthrough tumor-fighting methods within an environment of academic freedom. Anticipation of the late-stage trial results for an ovarian cancer therapy drug, with the current EPS at -0.70, serves as a key trigger. The business relies on external CROs and CMOs, fully outsourcing production and testing. This price chart clearly illustrates the price action of this asset.
Genelux Corporation - פילוחים אנליטיים ומדדי מפתח (GNLX)

Genelux Corporation's development of oncolytic viruses depends on the stability of global biomaterial supply chains. Logistics disruption risks directly impact earnings per share, which this indicator measures via a rolling annual change. The metric evaluates the net profit growth rate over 12 months, allowing for the determination of the business's competitive resilience relative to the sector. The rolling period year-over-year EPS growth trend helps identify the risk of overpaying for the asset.